ES2170812T3 - Pirrolocarbazoles fusionados. - Google Patents

Pirrolocarbazoles fusionados.

Info

Publication number
ES2170812T3
ES2170812T3 ES95938713T ES95938713T ES2170812T3 ES 2170812 T3 ES2170812 T3 ES 2170812T3 ES 95938713 T ES95938713 T ES 95938713T ES 95938713 T ES95938713 T ES 95938713T ES 2170812 T3 ES2170812 T3 ES 2170812T3
Authority
ES
Spain
Prior art keywords
inhibition
pirrolocarbazols
fusionated
compounds
mononeuronal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95938713T
Other languages
English (en)
Inventor
Robert L Hudkins
Ernest Knight Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27502273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2170812(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/323,755 external-priority patent/US5475110A/en
Priority claimed from US08/427,160 external-priority patent/US5591855A/en
Priority claimed from US08/452,335 external-priority patent/US5594009A/en
Application filed by Cephalon LLC filed Critical Cephalon LLC
Application granted granted Critical
Publication of ES2170812T3 publication Critical patent/ES2170812T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LO QUE AQUI SE DESCRIBE SON COMPUESTOS A LOS QUE SE LLAMA "PIRROLOCARBAZOLES FUSIONADOS" LOS CUALES POSEEN UNA VARIEDAD DE ACTIVIDADES FARMACOLOGICAS FUNCIONALES INCLUYENDO EFECTO SOBRE LA FUNCION Y/O SUPERVIVENCIA DE CELULAS RESPONSABLES DEL FACTOR TROFICO; INHIBICION DE ACTIVIDAD ENZIMATICA; INHIBICION DE RESPUESTAS ASOCIADAS A INFLAMACION; INHIBICION DE CRECIMIENTO DE CELULAS ASOCIADO A ESTADOS HIPERPROLIFERATIVOS; E INHIBICION DE MUERTE MONONEURONAL PROGRAMADO DE FORMA EXPERIMENTAL. LOS COMPUESTOS DESCRITOS ESTAN REPRESENTADOS POR LA FORMULA GENERAL (G). TAMBIEN SE DESCRIBEN METODOLOGIAS PARA LA PRODUCCION SINTETICA DE PIRROLOCARBAZOLES FUSIONADOS, ASI COMO USOS EJEMPLARES DE LOS COMPUESTOS.
ES95938713T 1994-10-14 1995-10-03 Pirrolocarbazoles fusionados. Expired - Lifetime ES2170812T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/323,755 US5475110A (en) 1994-10-14 1994-10-14 Fused Pyrrolocarbazoles
US08/427,160 US5591855A (en) 1994-10-14 1995-04-24 Fused pyrrolocarbazoles
US08/452,335 US5594009A (en) 1994-10-14 1995-05-26 Fused pyrrolocarbazoles
US08/526,798 US5705511A (en) 1994-10-14 1995-09-11 Fused pyrrolocarbazoles

Publications (1)

Publication Number Publication Date
ES2170812T3 true ES2170812T3 (es) 2002-08-16

Family

ID=27502273

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95938713T Expired - Lifetime ES2170812T3 (es) 1994-10-14 1995-10-03 Pirrolocarbazoles fusionados.
ES00204170T Expired - Lifetime ES2235769T3 (es) 1994-10-14 1995-10-03 Pirrolocarbazoles fusionados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00204170T Expired - Lifetime ES2235769T3 (es) 1994-10-14 1995-10-03 Pirrolocarbazoles fusionados.

Country Status (16)

Country Link
US (1) US5705511A (es)
EP (2) EP0785938B1 (es)
JP (1) JP2001509775A (es)
AT (2) ATE211472T1 (es)
AU (1) AU705306B2 (es)
BR (1) BR9509348A (es)
CA (1) CA2202487C (es)
DE (2) DE69533899T2 (es)
DK (2) DK1088823T3 (es)
ES (2) ES2170812T3 (es)
FI (1) FI115911B (es)
MX (1) MX9702682A (es)
NO (1) NO308996B1 (es)
NZ (1) NZ296244A (es)
PT (2) PT785938E (es)
WO (1) WO1996011933A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
NZ517497A (en) * 1997-08-15 2004-11-26 Cephalon Inc The synergistic effect of tyrosine kinase inhibitors and chemical castration agents in the treatment of prostate cancer
AU758241B2 (en) * 1998-03-13 2003-03-20 University Of British Columbia, The Granulatimide derivatives for use in cancer treatment
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
SK2542001A3 (en) * 1998-08-26 2002-06-04 Cephalon Inc Methods for modulating multiple lineage kinase proteins and for screening compounds which modulate multiple lineage kinase proteins
HK1040053B (en) 1998-09-25 2007-09-21 Cephalon, Inc. Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
BR0113266A (pt) * 2000-08-11 2005-01-04 Cephalon Inc Métodos para modular proteìnas quinase de linhagem múltipla e compostos protetores que modulam proteìnas quinase de linhagem múltipla
AU2001285205B2 (en) * 2000-08-25 2007-03-01 Cephalon, Inc. Fused pyrrolocarbazoles against inflammation
US6630500B2 (en) * 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
US6653290B2 (en) * 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
IL157909A0 (en) 2001-03-22 2004-03-28 Bristol Myers Squibb Co Indolopyrrolocarbazole derivatives and pharmaceutical compositions containing the same
US7018999B2 (en) * 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL144583A0 (en) 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
WO2003104482A1 (en) * 2002-06-05 2003-12-18 Metabolic Engineering Laboratories Co., Ltd. Signals and molecular species involved in senescence
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
FR2845997B1 (fr) * 2002-10-18 2004-12-24 Servier Lab Nouveaux derives de[1,4]benzodioxino[2,3-e]isoindole substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
US20060210553A1 (en) * 2003-07-23 2006-09-21 Creabilis Therapeutics S.R.L. Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excesssive cell proliferation
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
US7169802B2 (en) * 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
KR100734429B1 (ko) * 2004-12-06 2007-07-03 재단법인서울대학교산학협력재단 노화에 관여하는 신호 및 분자종
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
KR20080068848A (ko) 2005-10-11 2008-07-24 메르크 파텐트 게엠베하 케모카인 발현의 ｅｇｆｒ 의존적 조절 및 그의 종양 및부작용의 치료 및 진단효과
US20070249590A1 (en) * 2005-10-28 2007-10-25 Wilson Lawrence J Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
KR100831367B1 (ko) 2007-02-16 2008-05-22 재단법인서울대학교산학협력재단 아데닐일 시클라아제의 억제제를 노화 세포에 처리하는 단계를 포함하는 세포의 노화 조절방법 및 아데닐일 시클라아제의 억제제를 포함하는 세포 노화 조절용 조성물
CN101861159A (zh) * 2007-10-19 2010-10-13 马尔药品公司 改进的抗肿瘤治疗
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
CN103965204B (zh) * 2008-11-19 2016-09-07 赛福伦公司 吲唑并[5,4-a]吡咯并[3,4-c]咔唑化合物的新形式
EP2192121A1 (en) * 2008-11-27 2010-06-02 Cephalon France Regioselective reduction of fused pyrrolocarbazoles-5,7-diones
WO2010114267A2 (ko) * 2009-03-30 2010-10-07 덕산하이메탈(주) 유기전기소자 및 그 화합물, 단말
KR101182438B1 (ko) * 2009-08-14 2012-09-12 삼성디스플레이 주식회사 유기 발광 소자
KR102228358B1 (ko) 2012-12-21 2021-03-16 쉬케후세트 솔란데트 에이치에프 신경 장애 및 통증의 ｅｇｆｒ 표적 치료
WO2018136437A2 (en) 2017-01-17 2018-07-26 Tesaro, Inc. Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
DE102017117328A1 (de) * 2017-07-31 2019-01-31 Mitsubishi Polyester Film Gmbh Peelfähige Polyesterfolie, Verfahren zu ihrer Herstellung und ihre Verwendung
EP3823604A4 (en) 2018-07-17 2022-03-16 Board of Regents, The University of Texas System COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE
CN120737094A (zh) * 2025-06-27 2025-10-03 新昌县天姥实验室 一种thk01酯类前药及其制备方法和在制备抗炎药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552842A (en) * 1983-01-28 1985-11-12 Bristol-Myers Company Process for producing rebeccamycin
WO1988007045A1 (fr) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
DE3835842A1 (de) * 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
DE3833008A1 (de) * 1988-09-29 1990-04-05 Goedecke Ag Pyrrolocarbozol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US5185260A (en) * 1991-08-29 1993-02-09 The United States Of America As Represented By The United States Department Of Energy Method for distinguishing normal and transformed cells using G1 kinase inhibitors
NZ245203A (en) * 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US6271242B1 (en) * 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
DE4337521A1 (de) * 1993-11-03 1995-05-04 Teves Gmbh Alfred Verfahren zur Funktionsprüfung eines hydraulischen Aggregats

Also Published As

Publication number Publication date
DK1088823T3 (da) 2005-04-25
PT1088823E (pt) 2005-03-31
US5705511A (en) 1998-01-06
DE69524882D1 (de) 2002-02-07
EP1088823B1 (en) 2004-12-29
BR9509348A (pt) 1997-11-04
FI971479A0 (fi) 1997-04-09
FI115911B (fi) 2005-08-15
EP0785938A1 (en) 1997-07-30
HK1036622A1 (en) 2002-01-11
NO971677L (no) 1997-06-11
FI971479L (fi) 1997-06-11
ATE286055T1 (de) 2005-01-15
NO308996B1 (no) 2000-11-27
AU705306B2 (en) 1999-05-20
NO971677D0 (no) 1997-04-11
NZ296244A (en) 1998-11-25
EP0785938B1 (en) 2002-01-02
PT785938E (pt) 2002-06-28
JP2001509775A (ja) 2001-07-24
ATE211472T1 (de) 2002-01-15
CA2202487C (en) 2008-06-17
DE69524882T2 (de) 2002-09-12
WO1996011933A1 (en) 1996-04-25
AU3998695A (en) 1996-05-06
MX9702682A (es) 1998-02-28
DK0785938T3 (da) 2002-04-22
ES2235769T3 (es) 2005-07-16
DE69533899D1 (de) 2005-02-03
CA2202487A1 (en) 1996-04-25
DE69533899T2 (de) 2005-12-08
EP1088823A1 (en) 2001-04-04

Similar Documents

Publication Publication Date Title
MX9702682A (es) Pirrolocarbazoles fusionados.
CL2004001072A1 (es) Compuestos derivados de trifluorofenil-triazolopirimidina; procedimiento de preparacion de los compuestos; compuestos intermediarios utiles como fungicidas.
ATE27162T1 (de) C-076-verbindungen, deren herstellung und eine zuechtung fuer ihre herstellung.
ES2163445T3 (es) Pirimidinonas biciclicas fusionadas con actividad fungicida.
ES8604644A1 (es) Substrato de cultivo para las celulas, tejidos, organos vegetales y plantas enteras
CA2320304A1 (en) Fungicidal 7-alkyl-triazolopyrimidines
PT718293E (pt) Composto ciclodepsipeptidico
ES2102984T3 (es) Medios para el crecimiento de celulas y procedimiento para preparar los mismos.
ES2055713T3 (es) Antibioticos con actividad antifungica.
ES2096643T3 (es) Piridilsulfonilureas como herbicidas y reguladoras del crecimiento de las plantas, procedimientos para su preparacion y su utilizacion.
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
ES2087637T3 (es) Benzoilguanidinas sustituidas, procedimiento para su preparacion y su utilizacion como antiarritmicos.
ES2143004T3 (es) Derivados de la milbemicina, su preparacion y uso.
ES2141722T3 (es) Membranas con microorganismos inmovilizados en y/o sobre ellas, procedimiento para su preparacion, reactor que las comprenden y procedimiento que implica utilizacion de las mismas, en particular para eliminacion de metales o para degradacion de compuestos organicos xenobioticos.
ES2029160A6 (es) Procedimiento para la preparacion de nuevas azetidinas.
ES2057322T3 (es) Derivados de amida de aminoacido substituidos, su fabricacion y uso.
ES8603496A1 (es) Un procedimiento para la preparacion de nuevos derivados de cefalosporina
ES2038708T3 (es) Metodo para producir compuestos de benzotiepino(5,4-c)piridazina.
ATE61360T1 (de) Antioxidierend wirkende verbindungen, ihre herstellung und ihre verwendung.
ES8504693A1 (es) Procedimiento para la preparacion de sales organicas de n-fosfonometilglicina
EP0647625A4 (es)
ES2089661T3 (es) Soluciones para inyeccion de mesna.
AR006133A1 (es) Procedimiento para la preparacion de compuestos 4,6-bis(ariloxi)pirimidina asimetricos y un compuesto intermediario.
ATE53924T1 (de) Fungizide zur verwendung in der landwirtschaft und im gartenbau.
ES2087926T3 (es) Piridazinonas substituidas, procedimiento para su obtencion y su empleo como agentes pesticidas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 785938

Country of ref document: ES